In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats

Drug Metabolism and Disposition

Volumn 38, Issue 10, 2010, Pages 1848-1856

  Yanni, Souzan B ^a,b   Augustijns, Patrick F ^b   Benjamin Jr , Daniel K ^c   Brouwer, Kim L R ^a   Thakker, Dhiren R ^a   Annaert, Pieter P ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BILE ACID; BILE SALT; BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; FUMITREMORGIN C; GLYCOPROTEIN P; MICAFUNGIN; MULTIDRUG RESISTANCE PROTEIN 2; N [4 [2 (1,2,3,4 TETRAHYDRO 6,7 DIMETHOXY 2 ISOQUINOLINYL)ETHYL] PHENYL] 9,10 DIHYDRO 5 METHOXY 9 OXO 4 ACRIDINE CARBOXAMIDE; ORGANIC ANION TRANSPORTER; POLYPEPTIDE; PROTEIN INHIBITOR; RIFAMPICIN; SODIUM ION; SODIUM TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; TAUROCHOLIC ACID; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; BILE; BILIARY EXCRETION; BREAST CANCER; CANCER RESISTANCE; CELL CULTURE; DRUG CLEARANCE; DRUG EXCRETION; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL; LIVER TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; PSAMMOMYS OBESUS; PUMP; RAT;

ANIMALS; ANTIFUNGAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BILE CANALICULI; BILIARY TRACT; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHINOCANDINS; HEPATOCYTES; HUMANS; LIPOPEPTIDES; LIVER; MALE; METABOLIC DETOXICATION, DRUG; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; RATS; RATS, WISTAR; SYMPORTERS; TISSUE DISTRIBUTION;

RATTUS;

EID: 77957122213     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033811     Document Type: Article

References (41)

1. Abe F, Ueyama J, Kawasumi N, Nadai M, Hayashi T, Kato M, Ohnishi M, Saito H, Takeyama N, and Hasegawa T (2008a) Role of plasma proteins in pharmacokinetics of micafungin, an antifungal antibiotic, in analbuminemic rats. Antimicrob Agents Chemother 52:3454-3456.
2. Abe F, Ueyama J, Kimata A, Kato M, Hayashi T, Nadai M, Saito H, Takeyama N, Noguchi H, and Hasegawa T (2008b) Involvement of multidrug resistance-associated protein 2 (ABCC2/Mrp2) in biliary excretion of micafungin in rats. Life Sci 83:229-235.
3. Abe K, Bridges AS, Yue W, and Brouwer KLR (2008c) In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance. J Pharmacol Exp Ther 326:983-990.
4. Ahmed-Belkacem A, Pozza A, Macalou S, Pérez-Victoria JM, Boumendjel A, and Di Pietro A (2006) Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2). Anticancer Drugs 17:239-243.
5. Annaert PP and Brouwer KLR (2005) Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes. Drug Metab Dispos 33:388-394.
6. Annaert PP, Turncliff RZ, Booth CL, Thakker DR, and Brouwer KLR (2001) P-Glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes. Drug Metab Dispos 29:1277-1283.
7. Anonymous (2009) Micafungin: new drug. Severe candidiasis: a third echinocandin, with life-threatening hepatotoxicity. Prescrire Int 18:154.
8. Astellas Pharma US Inc. (2006) Mycamine® (micafungin sodium) for injection prescribing information. Astellas Pharma US Inc., Tokyo, Japan.
9. Björkman S (2005) Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 59:691-704.
10. Carver PL (2004) Micafungin. Ann Pharmacother 38:1707-1721.
11. Chandra P, Lecluyse EL, and Brouwer KLR (2001) Optimization of culture conditions for determining hepatobiliary disposition of taurocholate in sandwich-cultured rat hepatocytes. In Vitro Cell Dev Biol Anim 37:380-385.
12. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
13. Ghibellini G, Vasist LS, Leslie EM, Heizer WD, Kowalsky RJ, Calvo BF, and Brouwer KL (2007) In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clin Pharmacol Ther 81:406-413. (Pubitemid 46364478)
14. Hebert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J, and Bekersky I (2005b) Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45:1018-1024. (Pubitemid 41192360)
15. Hebert MF, Townsend RW, Austin S, Balan G, Blough DK, Buell D, Keirns J, and Bekersky I (2005a) Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45:954-960. (Pubitemid 41060236)
16. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, and Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
17. 5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J Pharmacol Exp Ther 311:1203-1210.
18. Janneh O, Owen A, Bray PG, Back DJ, and Pirmohamed M (2010) The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. Br J Pharmacol 159:484-493.
19. Kaneko H, Yamato Y, Teramura Y, Fujiwara T, Suzuki A, Kawarura A, Terakawa M, and Kagayama A (2002) Metabolites of micafungin in rats and dogs. Jpn J Chemother 50 (Suppl 1):88-93.
20. Kemp DC, Zamek-Gliszczynski MJ, and Brouwer KLR (2005) Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol Sci 83:207-214.
21. Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, Mireles R, Feng B, Kubik R, Hanson J, Urda E, and Mutlib AE (2006) Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 90:451-459.
22. +-taurocholate cotransporting green fluorescent protein in human hepatoblastoma HepG2 cells. Cytotechnology 34:1-9.
23. LeCluyse EL and Brouwer KLR, and Liu X (2001) inventors; University of North Carolina, assignee. Method of screening candidate compounds for susceptibility to biliary excretion. European Union patent EP1163517. 2001 Dec 19.
24. LeCluyse EL, Brouwer KLR, and Liu X (2004) inventors; University of North Carolina at Chapel Hill, assignee. Method of screening candidate compounds for susceptibility to biliary excretion. U.S. patent 6,780,580. 2004 Aug 25.
25. +-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther 321:1170-1178.
26. Liu X, Chism JP, LeCluyse EL, Brouwer KR, and Brouwer KLR (1999a) Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 27:637-644. (Pubitemid 29252436)
27. Marion TL, Leslie EM, and Brouwer KLR (2007) Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol Pharm 4:911-918.
28. Maruyama T, Takei Y, Gabazza EC, Morser J, and Taguchi O (2009) Different bile concentration of micafungin and itraconazole in a patient with candidal cholecystitis. J Infect 58:315-316.
29. Matsson P, Pedersen JM, Norinder U, Bergström CA, and Artursson P (2009) Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816-1831.
30. McRae MP, Lowe CM, Tian X, Bourdet DL, Ho RH, Leake BF, Kim RB, Brouwer KLR, and Kashuba AD (2006) Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther 318:1068-1075.
31. +/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos 34:1575-1581.
32. Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, and Okumura K (2005) Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol 57:759-764.
33. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, and Kim RB (2005) Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 33:676-682. (Pubitemid 40593883)
34. +-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol 274:G370-G375.
35. Shitara Y, Nagamatsu Y, Wada S, Sugiyama Y, and Horie T (2009) Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin A in rats. Drug Metab Dispos 37:1172-1178.
36. Su Y, Zhang X, and Sinko PJ (2004) Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm 1:49-56.
37. Wiederhold NP and Lewis JS 2nd (2007) The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother 8:1155-1166.
38. Xiong H, Suzuki H, Sugiyama Y, Meier PJ, Pollack GM, and Brouwer KLR (2002) Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metab Dispos 30:962-969.
39. Yamato Y, Kaneko H, Hashimoto T, Katashima M, Ishibashi K, Kawarura A, Terakawa M, and Kagayama A (2002) Pharmacokinetics of the antifungal drug micafungin in mice, rats and dogs, and its in vitro protein binding and distribution to blood cells. Jpn J Chemother 50 (Suppl 1):74-79.
40. Ye ZW, Augustijns P, and Annaert P (2008) Cellular accumulation of cholyl-glycylamidofluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors. Drug Metab Dispos 36:1315-1321. (Pubitemid 351929316)
41. Ye ZW, Van Pelt J, Camus S, Snoeys J, Augustijns P, and Annaert P (2010) Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes. J Pharm Sci 99:2886-2898.